The effect of dried plum on serum levels of receptor activator of NF-κB ligand, osteoprotegerin and sclerostin in osteopenic postmenopausal women: A randomised controlled trial

British Journal of Nutrition

Volumn 112, Issue 1, 2014, Pages 55-60

  Hooshmand, Shirin ^a   Brisco, Jayme R Y ^a   Arjmandi, Bahram H ^b  

^a SAN DIEGO STATE UNIVERSITY   (United States)

^b FLORIDA STATE UNIVERSITY   (United States)

Author keywords

Dried plum; Osteoporosis; Osteoprotegerin; Postmenopausal women; Receptor activator of NF B ligand; Sclerostin

Indexed keywords

BIOLOGICAL MARKER; CALCIUM; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLANT MEDICINAL PRODUCT; SCLEROSTIN; VITAMIN D;

ADULT; ARTICLE; BLOOD SAMPLING; BONE DENSITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOOD INTAKE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPENIA; PLUM; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; CLINICAL EFFECTIVENESS; DIET SUPPLEMENTATION; DIETARY INTAKE; FOREARM; HIP; LUMBAR SPINE; OUTCOME ASSESSMENT; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN SYNTHESIS REGULATION; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; ULNA;

PRUNUS DOMESTICA;

BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE MORPHOGENETIC PROTEINS; CALCIUM, DIETARY; CALIFORNIA; COMBINED MODALITY THERAPY; DIETARY SUPPLEMENTS; FEMALE; FOOD, PRESERVED; FRUIT; GENETIC MARKERS; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; OSTEOPROTEGERIN; PRUNUS; RANK LIGAND; RISK; SEVERITY OF ILLNESS INDEX; VITAMIN D;

EID: 84902543758     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114514000671     Document Type: Article

References (30)

1. Weitzmann MN & Pacifici R (2006) Estrogen deficiency and bone loss: an inflammatory tale. J Clin Investig 116, 1186-1194.
2. Weycker D, Macarios D, Edelsberg J, et al. (2007) Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 18, 271-277.
3. Gogakos AI, Cheung MS, Bassett JHD, et al. (2009) Bone signaling pathways and treatment of osteoporosis. Expert Rev Endocrinol Metabol 4, 639-650.
4. Huybrechts KF, Ishak KJ & Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38, 922-928.
5. Deyhim F, Stoecker BJ, Brusewitz GH, et al. (2005) Dried plum reverses bone loss in an osteopenic rat model of osteoporosis. Menopause 12, 755-762.
6. Bu SY, Lucas EA, Franklin M, et al. (2007) Comparison of dried plum supplementation and intermittent PTH in restoring bone in osteopenic orchidectomized rats. Osteoporos Int 18, 931-942.
7. Halloran BP, Wronski TJ, VonHerzen DC, et al. (2010) Dietary dried plum increases bone mass in adult and aged male mice. J Nutr 140, 1781-1787.
8. Arjmandi BH, Khalil DA, Lucas EA, et al. (2002) Dried plums improve indices of bone formation in postmenopausal women. J Womens Health Gend Based Med 11, 61-68.
9. Hooshmand S, Chai SC, Saadat RL, et al. (2011) Comparative effects of dried plum and dried apple on bone in postmenopausal women. Br J Nutr 106, 923-930.
10. Franklin M, Bu SY, Lerner MR, et al. (2006) Dried plum prevents bone loss in a male osteoporosis model via IGF-I and the RANK pathway. Bone 39, 1331-1342.
11. Galli C, Passeri G & Macaluso GM (2010) Osteocytes and WNT: the mechanical control of bone formation. J Dent Res 89, 331-343.
12. Xiong J & O'Brien CA (2012) Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res 27, 499-505.
13. Boyle WJ, Simonet WS & Lacey DL (2003) Osteoclast differentiation and activation. Nature 423, 337-342.
14. Kostenuik PJ (2005) Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 5, 618-625.
15. Jabbar S, Drury J, Fordham JN, et al. (2011) Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis. J Clin Pathol 64, 354-357.
16. Moester MJ, Papapoulos SE, Lowik CW, et al. (2010) Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 87, 99-107.
17. Watts N (2011) The fracture risk assessment tool (FRAXw): applications in clinical practice. J Womens Health 20, 525-531.
18. Finkelstein J, Brockwell S, Mehta V, et al. (2008) Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 93, 861-868.
19. Arjmandi BH, Lucas EA, Juma S, et al. (2001) Dried plums prevent ovariectomy-induced bone loss in rats. J Am Nutraceutical Assoc 4, 50-56.
20. Arjmandi BH, Johnson CD, Campbell SC, et al. (2010) Combining fructooligosaccharide and dried plum has the greatest effect on restoring bone mineral density among select functional foods and bioactive compounds. J Med Food 13, 312-319.
21. Johnson CD, Lucas EA, Hooshmand S, et al. (2011) Addition of fructooligosaccharides and dried plum to soy-based diets reverses bone loss in the ovariectomized rat. Evid Based Complement Alternat Med 8, 362-367.
22. Findlay DM & Atkins GJ (2011) Relationship between serum RANKL and RANKL in bone. Osteoporos Intern 22, 2597-2602.
23. Rogers A & Eastell R (2005) Circulating osteoprotegerin and receptor activator for nuclear factor kB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 90, 6323-6331.
24. Findlay D, Chehade M, Tsangari H, et al. (2008) Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males. Arthritis Res Ther 10, R2.
25. Drake MT, Srinivasan B, Mödder UI, et al. (2010) Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95, 5056-5062.
26. Reyes-Garcia R, Muñoz-Torres M, Garcia DF, et al. (2010) Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kB in women with postmenopausal osteoporosis. J N Am Menopause Soc 17, 140-144.
27. Guo B, Peng S, Liang C, et al. (2012) Recent developments in bone anabolic therapy for osteoporosis. Expert Rev Endocrinol Metab 7, 677-685.
28. Mirza FS, Padhi ID, Raisz LG, et al. (2010) Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95, 1991-1997.
29. Costa AG & Bilezikian JP (2012) Sclerostin: therapeutic horizons based upon its actions. Curr Osteoporos Rep 10, 64-72.
30. Silverman S (2010) Sclerostin. J Osteoporos 2010, 941419.